Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID

BACKGROUND: Strimvelis (autologous CD34+ cells transduced to express adenosine deaminase [ADA]) is the first ex vivo stem cell gene therapy approved by the European Medicines Agency (EMA), indicated as a single treatment for patients with ADA-severe combined immunodeficiency (ADA-SCID) who lack a su...

Descripción completa

Detalles Bibliográficos
Autores principales: Stirnadel-Farrant, Heide, Kudari, Mahesh, Garman, Nadia, Imrie, Jessica, Chopra, Bikramjit, Giannelli, Stefania, Gabaldo, Michela, Corti, Ambra, Zancan, Stefano, Aiuti, Alessandro, Cicalese, Maria Pia, Batta, Rohit, Appleby, Jonathan, Davinelli, Mario, Ng, Pauline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889583/
https://www.ncbi.nlm.nih.gov/pubmed/29625577
http://dx.doi.org/10.1186/s13023-018-0791-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889583/
https://www.ncbi.nlm.nih.gov/pubmed/29625577
http://dx.doi.org/10.1186/s13023-018-0791-9

Ejemplares similares